Zydus Cadila has announced that it has received the final approval from the US Food and Drug Administration (FDA) to market ranolazine extended─release tablets (Ranexa), 500 mg and 1,000 mg. The drug is used to treat chronic angina and may be used with other medicines that are used for heart problems and blood pressure control.
